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RESEARCH LETTER
Fixed drug eruption due to etoricoxibe -- A
case  reportp
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nTo  the  Editor,
Fixed  drug  eruption  (FDE)  is  a  commonly  reported
adverse  drug  reaction,  characterized  by  single  or  multiple
round  oedematous  erythemato-violaceous  plaques  with  well
deﬁned  borders  and  often  central  bullous  detachments.1,2
Lesions  usually  develop  48  h  after  drug  intake  and  recur  at
the  same  sites  upon  reexposure  to  the  offending  drug.3,4
Spontaneous  resolution  with  residual  hyperpigmented  post-
inﬂammatory  patches  is  also  characteristic.3,4
Non-steroidal  anti  inﬂammatory  drugs  (NSAIDs),  in  partic-
ular  nimesulide  and  piroxicam,  are  the  most  frequent  culprit
agents,  followed  by  antibiotics  and  anticonvulsants.1,3,4
Etoricoxib  is  a  recently  developed  selective  cyclo-
oxygenase  (COX)  isoenzyme  2  inhibitor  which  has  rarely  been
described  as  a  cause  of  FDE.5--8
We  report  a  case  of  ﬁxed  drug  eruption  due  to  etoricoxib.
A  38-year-old  man  with  allergic  rhinitis  and  no  history  of  drug
allergy  was  referred  to  our  outpatient  clinic  due  to  multiple
sharp  round  erythematous  pruriginous  patches  of  diameter
1--4  cm  on  the  upper  and  lower  limbs,  trunk  and  genitals.
The  patient  mentioned  several  exacerbations  along  the  pre-
vious  year,  approximately  once  a  month.  In  most  episodes
no  triggering  factor  could  be  determined  but  in  two  occa-
sions  he  noticed  that  lesions  relapsed  15--30  min  after  intake
of  etoricoxib,  frequently  taken  by  the  patient  for  muscu-
loskeletal  pain.  There  was  spontaneous  improvement  after
3--4  days  after  stopping  NSAIDs  intake,  but  multiple  residual
hyperpigmented  lesions  persisted  for  several  months.  The
patient  mentioned  regular  consumption  of  paracetamol  and
ibuprofen  for  headaches  or  musculoskeletal  pain,  apparently
with  no  adverse  reaction.
The  patient  underwent  patch  testing  with  paracetamol,
ibuprofen,  nimesulide  and  etoricoxib  (30%  in  petrolatum),
applied  to  the  hyperpigmented  lesion  in  the  right  forearm.
Patch  tests  were  performed  several  months  after  the  resolu-
tion  of  the  last  adverse  reaction.  An  erythematous  papular
reaction  was  observed  with  etoricoxib  on  the  lesional  skin
48  h  and  96  h  later  (Fig.  1).  A  pruriginous  ﬂare  in  one  single
residual  lesion  of  the  trunk  was  also  reported.  The  patchPlease  cite  this  article  in  press  as:  Antunes  J,  et  al.  Fixed  dr
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tests  with  the  other  three  drugs  were  negative.
No  ﬂares  of  FDE  occurred  after  withdrawal  of  etoricoxib
and  reexposure  to  nimesulide,  ibuprofen  and  paracetamol
did  not  cause  recurrence  of  the  lesions  (self  initiative).
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http://dx.doi.org/10.1016/j.aller.2013.06.003Figure  1  Patch  test  with  etoricoxib  (48  h  reading).
In  our  case,  the  culprit  drug  was  promptly  conﬁrmed  by
atch  testing  on  residual  lesions,  as  described  for  several
SAIDs,  including  etoricoxib.1--4
Despite  being  a  recent  drug,  etoricoxib  is  widely  used
n  many  countries.  Because  of  its  high  level  of  COX2/COX1
electivity,  it  combines  high  anti-inﬂammatory  activity
equivalent  or  superior  to  that  of  conventional  NSAIDs)  with
 lower  incidence  of  side  effects.9 The  most  commonly
eported  cutaneous  reactions  due  to  etoricoxib  are  urticaria
nd  angioedema  followed  by  sporadic  cases  of  erythema
ultiforme,  Stevens--Johnson  syndrome,  acute  generalized
xanthematous  pustulosis  and  rarely  FDE.5--10
Patch  testing  has  been  widely  recommended  as  the  ini-
ial  diagnostic  tool  in  FDE  patients.1--4 This  method  is  useful
n  the  etiologic  investigation  of  FDE  and  avoids  the  risks
f  systemic  drug  reexposure.  Although  pure  allergens  are
ommercially  available  for  some  drugs,  others  must  be  pre-
ared  by  using  the  powder  of  commercial  tablets  in  pet
recommended  concentrations  between  5%  and  30%).3 We
dopted  the  maximum  recommend  concentration  (i.e.  30%
n  petrolatum  for  commercial  tablets)  in  order  to  avoid  false-
egative  results.
The  rationale  for  patch  testing  on  lesional  skin  resides
n  the  activation  of  intra-epidermal  memory  T  cells  by
he  re-exposure  to  the  offending  drug.8 Non-lesional  skinug  eruption  due  to  etoricoxibe  --  A  case  report.  Allergol
.2013.06.003
atch  tests  are  useful  only  for  control  purposes  and  nega-
ive  results  are  expected  in  the  vast  majority  of  patients.1,4
aña, S.L. All rights reserved.
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or  this  reason,  we  only  applied  the  drugs  on  lesional
kin.
Drug  eviction  is  the  mainstay  of  treatment  in  non-IgE
ediated  drug  allergy.  In  our  case,  as  other  NSAIDs  were
vailable  and  well  tolerated  by  the  patient,  we  recom-
ended  the  eviction  of  all  selective  COX2  inhibitors.  Until
ow  no  cross-reactivity  has  been  described  between  these
olecules  possibly  due  to  differences  in  the  molecular  struc-
ure  of  etoricoxib.5,7,10 However,  more  data  are  still  required
efore  assuming  the  absence  of  cross-reactivity  between
ifferent  COX2  inhibitors.
In this  case,  as  sustained  by  literature,  patch  testing  was
f  unquestionable  value  in  the  identiﬁcation  of  the  culprit
gent.  More  research  is  still  required  for  standardization
f  this  technique,  particularly  for  drugs  exclusively  avail-
ble  as  commercial  tablets.  Patch  testing  was  also  useful  in
he  search  for  safe  alternative  drugs.  Although  a  drug  chal-
enge  is  required  for  deﬁnite  conﬁrmation,  the  patient  had
sed  several  other  NSAIDs  with  no  reaction,  obviating  the
eed  for  further  procedures.  Finally,  even  though  etoricoxib
s  a  safe  drug,  a  high  suspicion  index  is  required  in  patients
ith  FDE.
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